NCT06142357 - Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis | Biotech Hunter

Enrollment

188

Participants

Timeline

Start Date

December 29, 2023

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions

Moderate-to-severe Plaque Psoriasis

Interventions

OTHER

Secukinumab

There is no treatment allocation. Patients administered secukinumab by prescription will be enrolled

Trial Locations (16)

105007

Novartis Investigative Site, Moscow

117513

Novartis Investigative Site, Moscow

119296

Novartis Investigative Site, Moscow

119435

Novartis Investigative Site, Moscow

141009

Novartis Investigative Site, Mytishchi

300053

Novartis Investigative Site, Tula

344022

Novartis Investigative Site, Rostov-on-Don

364022

Novartis Investigative Site, Grozny

420012

Novartis Investigative Site, Kazan'

426009

Novartis Investigative Site, Izhevsk

445846

Novartis Investigative Site, Tolyatti

450000

Novartis Investigative Site, Ufa

454048

Novartis Investigative Site, Chelyabinsk

603950

Novartis Investigative Site, Nizhny Novgorod

650025

Novartis Investigative Site, Kemerovo

677000

Novartis Investigative Site, Yakutsk